Harvard Bioscience (NASDAQ: HBIO) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations.

Valuation & Earnings

This table compares Harvard Bioscience and Accelerate Diagnostics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harvard Bioscience $101.88 million 2.06 -$860,000.00 $0.05 118.00
Accelerate Diagnostics $4.18 million 307.65 -$64.02 million ($1.16) -19.87

Harvard Bioscience has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

62.7% of Harvard Bioscience shares are held by institutional investors. Comparatively, 44.9% of Accelerate Diagnostics shares are held by institutional investors. 7.6% of Harvard Bioscience shares are held by company insiders. Comparatively, 50.0% of Accelerate Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Harvard Bioscience and Accelerate Diagnostics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harvard Bioscience 0 0 2 0 3.00
Accelerate Diagnostics 0 1 1 0 2.50

Harvard Bioscience currently has a consensus price target of $9.00, suggesting a potential upside of 52.54%. Accelerate Diagnostics has a consensus price target of $33.00, suggesting a potential upside of 43.17%. Given Harvard Bioscience’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Harvard Bioscience is more favorable than Accelerate Diagnostics.

Profitability

This table compares Harvard Bioscience and Accelerate Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Harvard Bioscience -0.85% 2.34% 1.64%
Accelerate Diagnostics -1,520.99% -54.66% -51.90%

Volatility and Risk

Harvard Bioscience has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500.

Summary

Harvard Bioscience beats Accelerate Diagnostics on 10 of the 13 factors compared between the two stocks.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names. It also designs, develops, and manufactures precision electrophysiology equipment specializing in patch clamp amplifiers, and manual and automated patch clamp systems under the HEKA brand; manufactures tools for electrophysiology and cell biology research consisting of cell chambers, perfusion controllers, temperature controllers, microincubation systems, and bio-sensing systems under the Warner Instruments brand; and designs and develops in vivo neural interface systems under the TBSI brand for neuroscience research, primarily in the fields of electrophysiology, psychology, neurology, and pharmacology. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions. Harvard Bioscience, Inc. markets its products in approximately 100 countries through sales organization, Websites, catalogs, and distributors to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.